5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer

M. Merlano, A. Bacigalupo, M. Benasso, A. Grimaldi, S. Toma, G. Benedetti, G. Comella, F. Cacace, R. Rosso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Experimental and clinical data support the concomitant use of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA). To verify the role of such a combination in far advanced head and neck cancer, we performed a phase II study employing weekly HDFA, 500 mg/m2 in 2-h infusions, and 5-FU, 600 mg/m2 bolus injection. Twenty-seven evaluable patients with recurrent disease entered the study. One complete response, seven partial responses, 10 stable disease, and nine progressions were observed: the overall response rate was 29.6%. Oral mucositis and diarrhea were major side effects; five patients discontinued the treatment due to toxicity; no deaths correlated to the treatment were detected. Considering the characteristics of our patients, the 5-FU/HDFA combination has shown a satisfactory antitumoral activity, but toxicity was similar to other chemotherapy regimens.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number1
Publication statusPublished - 1990

Fingerprint

Leucovorin
Head and Neck Neoplasms
Fluorouracil
Drug Therapy
Stomatitis
Disease Progression
Diarrhea
Injections
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer. / Merlano, M.; Bacigalupo, A.; Benasso, M.; Grimaldi, A.; Toma, S.; Benedetti, G.; Comella, G.; Cacace, F.; Rosso, R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 1, 1990, p. 1-3.

Research output: Contribution to journalArticle

Merlano, M, Bacigalupo, A, Benasso, M, Grimaldi, A, Toma, S, Benedetti, G, Comella, G, Cacace, F & Rosso, R 1990, '5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 13, no. 1, pp. 1-3.
Merlano, M. ; Bacigalupo, A. ; Benasso, M. ; Grimaldi, A. ; Toma, S. ; Benedetti, G. ; Comella, G. ; Cacace, F. ; Rosso, R. / 5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 1. pp. 1-3.
@article{0f12f08b2dd442e0af87ccfbfbff786d,
title = "5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer",
abstract = "Experimental and clinical data support the concomitant use of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA). To verify the role of such a combination in far advanced head and neck cancer, we performed a phase II study employing weekly HDFA, 500 mg/m2 in 2-h infusions, and 5-FU, 600 mg/m2 bolus injection. Twenty-seven evaluable patients with recurrent disease entered the study. One complete response, seven partial responses, 10 stable disease, and nine progressions were observed: the overall response rate was 29.6{\%}. Oral mucositis and diarrhea were major side effects; five patients discontinued the treatment due to toxicity; no deaths correlated to the treatment were detected. Considering the characteristics of our patients, the 5-FU/HDFA combination has shown a satisfactory antitumoral activity, but toxicity was similar to other chemotherapy regimens.",
author = "M. Merlano and A. Bacigalupo and M. Benasso and A. Grimaldi and S. Toma and G. Benedetti and G. Comella and F. Cacace and R. Rosso",
year = "1990",
language = "English",
volume = "13",
pages = "1--3",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - 5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer

AU - Merlano, M.

AU - Bacigalupo, A.

AU - Benasso, M.

AU - Grimaldi, A.

AU - Toma, S.

AU - Benedetti, G.

AU - Comella, G.

AU - Cacace, F.

AU - Rosso, R.

PY - 1990

Y1 - 1990

N2 - Experimental and clinical data support the concomitant use of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA). To verify the role of such a combination in far advanced head and neck cancer, we performed a phase II study employing weekly HDFA, 500 mg/m2 in 2-h infusions, and 5-FU, 600 mg/m2 bolus injection. Twenty-seven evaluable patients with recurrent disease entered the study. One complete response, seven partial responses, 10 stable disease, and nine progressions were observed: the overall response rate was 29.6%. Oral mucositis and diarrhea were major side effects; five patients discontinued the treatment due to toxicity; no deaths correlated to the treatment were detected. Considering the characteristics of our patients, the 5-FU/HDFA combination has shown a satisfactory antitumoral activity, but toxicity was similar to other chemotherapy regimens.

AB - Experimental and clinical data support the concomitant use of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA). To verify the role of such a combination in far advanced head and neck cancer, we performed a phase II study employing weekly HDFA, 500 mg/m2 in 2-h infusions, and 5-FU, 600 mg/m2 bolus injection. Twenty-seven evaluable patients with recurrent disease entered the study. One complete response, seven partial responses, 10 stable disease, and nine progressions were observed: the overall response rate was 29.6%. Oral mucositis and diarrhea were major side effects; five patients discontinued the treatment due to toxicity; no deaths correlated to the treatment were detected. Considering the characteristics of our patients, the 5-FU/HDFA combination has shown a satisfactory antitumoral activity, but toxicity was similar to other chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0025211807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025211807&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1

EP - 3

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -